

On page 10, line 11, change "Figure 6, comprising panels A and B, shows" to read "Figures 6A and 6B".

On page 10, line 22, change "Figure 9, comprising panels A and B, depicts" to read "Figures 9A and 9B depict".

On page 10, line 23, change "panel (A)" to read "(Figure 9A)" and "panel (B)" to read "(Figure 9B)".

On page 10, line 25, change "panel (A)" to read "(Figure 9A)".

On page 10, line 26, change "panel (B)" to read "(Figure 9B)".

On page 10, line 27, change "Figure 10, comprising panels A and B, depicts" to read "Figures 10A and 10B depict".

On page 10, line 29, change "panel (A)" to read "(Figure 10A)".

On page 10, line 30, change "panel (B)" to read "(Figure 10B)".

On page 19, lines 16 to 17, change "12301 Parklawn Drive, Rockville, Maryland, USA, 20852" to read "10801 University Blvd., Manassas, VA 20110-2209".

On page 20, line 15, change "GENE AMP (trademark)".

On page 20, line 32, change "Fast Track" to read "FAST TRACK (trademark)".

On page 20, line 34, change "cDMA synthesis Plus" to "cDMA SYNTHESIS PLUS (trademark)".

On page 21, line 1, change "cDMA Cloning System-λgt10" to read "cDNA CLONING SYSTEM-λgt10 (trademark)".

On page 21, line 9, change "Random priming system I" to read "RANDOM PRIMING SYSTEM I(trademark)".

In the Claims:

Amend claims 1 to 11 and 27 as follows:

1. (Twice Amended) A recombinant conjugate antibody molecule, consisting of a bivalent monoclonal antibody moiety having the entire heavy and light chains and specific for a surface structure of antigen presenting cells, said monoclonal antibody moiety being genetically modified to contain at least one antigen moiety, each said antigen moiety being located exclusively at a [at least one] preselected site on said monoclonal antibody moiety, whereby said conjugate antibody molecule is capable